Kathryn Hassell
Concepts (520)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anemia, Sickle Cell | 45 | 2025 | 254 | 7.140 |
Why?
| Water Pollutants, Chemical | 13 | 2022 | 205 | 2.310 |
Why?
| Antiphospholipid Syndrome | 5 | 2023 | 37 | 1.830 |
Why?
| Migraine Disorders | 2 | 2023 | 101 | 1.370 |
Why?
| Anticoagulants | 8 | 2021 | 636 | 1.260 |
Why?
| Perciformes | 5 | 2018 | 17 | 1.200 |
Why?
| Heparin | 5 | 2011 | 253 | 1.140 |
Why?
| Thrombocytopenia | 5 | 2014 | 186 | 1.140 |
Why?
| Fishes | 4 | 2021 | 95 | 1.080 |
Why?
| Antibodies, Antiphospholipid | 4 | 2023 | 26 | 1.070 |
Why?
| Estrogens | 3 | 2016 | 347 | 0.840 |
Why?
| Hydroxyurea | 5 | 2016 | 34 | 0.820 |
Why?
| Hypertension, Pulmonary | 11 | 2025 | 1894 | 0.790 |
Why?
| Pyridones | 2 | 2021 | 159 | 0.760 |
Why?
| Blood Transfusion | 7 | 2015 | 296 | 0.750 |
Why?
| Disorders of Sex Development | 2 | 2018 | 39 | 0.720 |
Why?
| Hirudins | 4 | 2011 | 52 | 0.700 |
Why?
| Fibrinolytic Agents | 2 | 2021 | 263 | 0.680 |
Why?
| Hemoglobins | 8 | 2021 | 339 | 0.680 |
Why?
| Testis | 2 | 2018 | 144 | 0.680 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2023 | 247 | 0.670 |
Why?
| Pyrazoles | 2 | 2021 | 405 | 0.670 |
Why?
| Caprylates | 1 | 2020 | 22 | 0.660 |
Why?
| Alkanesulfonic Acids | 1 | 2020 | 34 | 0.650 |
Why?
| Quality of Life | 6 | 2017 | 2704 | 0.610 |
Why?
| Oocytes | 2 | 2021 | 176 | 0.610 |
Why?
| Environmental Monitoring | 7 | 2022 | 318 | 0.590 |
Why?
| Fluorocarbons | 1 | 2020 | 109 | 0.580 |
Why?
| Neonatal Screening | 3 | 2020 | 163 | 0.570 |
Why?
| Hemopexin | 3 | 2025 | 27 | 0.560 |
Why?
| Cyprinidae | 1 | 2016 | 20 | 0.520 |
Why?
| Australia | 10 | 2022 | 243 | 0.520 |
Why?
| Pain | 5 | 2023 | 789 | 0.490 |
Why?
| Surveys and Questionnaires | 4 | 2017 | 5401 | 0.440 |
Why?
| Pain Measurement | 3 | 2017 | 506 | 0.440 |
Why?
| beta-Thalassemia | 2 | 2025 | 37 | 0.440 |
Why?
| Embryo, Nonmammalian | 2 | 2019 | 166 | 0.430 |
Why?
| Health Status Indicators | 1 | 2014 | 167 | 0.430 |
Why?
| Patient Outcome Assessment | 1 | 2014 | 125 | 0.420 |
Why?
| Adult | 41 | 2025 | 35572 | 0.410 |
Why?
| Tricuspid Valve Insufficiency | 3 | 2011 | 24 | 0.400 |
Why?
| Humans | 75 | 2025 | 129621 | 0.400 |
Why?
| Peptide Fragments | 4 | 2014 | 692 | 0.380 |
Why?
| Thrombosis | 4 | 2021 | 343 | 0.370 |
Why?
| Antithrombins | 2 | 2011 | 58 | 0.370 |
Why?
| Empirical Research | 1 | 2011 | 21 | 0.360 |
Why?
| Male | 47 | 2025 | 63674 | 0.360 |
Why?
| Nomograms | 1 | 2011 | 47 | 0.350 |
Why?
| Evidence-Based Medicine | 5 | 2017 | 718 | 0.340 |
Why?
| Censuses | 1 | 2010 | 27 | 0.340 |
Why?
| Animals | 28 | 2025 | 35360 | 0.330 |
Why?
| Female | 43 | 2025 | 68770 | 0.330 |
Why?
| Endocrine Disruptors | 3 | 2016 | 40 | 0.330 |
Why?
| Rivaroxaban | 2 | 2025 | 252 | 0.320 |
Why?
| Venous Thromboembolism | 2 | 2025 | 284 | 0.320 |
Why?
| Vitellogenins | 3 | 2016 | 10 | 0.310 |
Why?
| Young Adult | 18 | 2025 | 12426 | 0.310 |
Why?
| Heme | 3 | 2025 | 77 | 0.310 |
Why?
| Health Priorities | 1 | 2009 | 34 | 0.310 |
Why?
| Thrombophilia | 3 | 2007 | 81 | 0.310 |
Why?
| Carotid Artery, Internal, Dissection | 1 | 2008 | 13 | 0.290 |
Why?
| Stroke | 3 | 2021 | 1071 | 0.290 |
Why?
| Estuaries | 2 | 2021 | 3 | 0.290 |
Why?
| Self Care | 1 | 2010 | 369 | 0.280 |
Why?
| Gonads | 2 | 2018 | 23 | 0.280 |
Why?
| Population Surveillance | 2 | 2010 | 439 | 0.280 |
Why?
| Middle Aged | 25 | 2025 | 31150 | 0.280 |
Why?
| Heart Septal Defects, Atrial | 2 | 2005 | 52 | 0.280 |
Why?
| Hospitalists | 1 | 2011 | 229 | 0.270 |
Why?
| Sickle Cell Trait | 2 | 2018 | 13 | 0.270 |
Why?
| Fresh Water | 3 | 2020 | 54 | 0.270 |
Why?
| Nitric Oxide | 2 | 2018 | 902 | 0.270 |
Why?
| Biodiversity | 2 | 2021 | 380 | 0.270 |
Why?
| Haptoglobins | 2 | 2018 | 52 | 0.260 |
Why?
| Estradiol | 4 | 2016 | 494 | 0.260 |
Why?
| Insecta | 1 | 2006 | 65 | 0.260 |
Why?
| Kinetics | 2 | 2020 | 1642 | 0.260 |
Why?
| Phospholipids | 1 | 2008 | 215 | 0.260 |
Why?
| Environmental Pollutants | 2 | 2019 | 143 | 0.250 |
Why?
| Health Services Accessibility | 3 | 2016 | 902 | 0.250 |
Why?
| Pregnancy Complications, Hematologic | 1 | 2005 | 20 | 0.250 |
Why?
| Patient Education as Topic | 1 | 2010 | 741 | 0.250 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2025 | 573 | 0.240 |
Why?
| Adolescent | 20 | 2025 | 20391 | 0.240 |
Why?
| Iron | 3 | 2025 | 288 | 0.240 |
Why?
| Hospitalization | 4 | 2025 | 2070 | 0.240 |
Why?
| Estrone | 2 | 2016 | 37 | 0.230 |
Why?
| Spleen | 2 | 2025 | 507 | 0.230 |
Why?
| Factor Xa Inhibitors | 1 | 2025 | 170 | 0.210 |
Why?
| Cadmium | 2 | 2021 | 67 | 0.210 |
Why?
| Hemoglobinopathies | 1 | 2023 | 4 | 0.210 |
Why?
| Mass Screening | 1 | 2011 | 1149 | 0.210 |
Why?
| Hemostasis | 2 | 2007 | 79 | 0.210 |
Why?
| Antisickling Agents | 2 | 2016 | 7 | 0.210 |
Why?
| Headache | 2 | 2023 | 151 | 0.200 |
Why?
| Wetlands | 2 | 2022 | 33 | 0.200 |
Why?
| Child | 20 | 2024 | 20882 | 0.200 |
Why?
| Lung | 3 | 2025 | 3931 | 0.200 |
Why?
| Bays | 3 | 2017 | 6 | 0.200 |
Why?
| Psychometrics | 3 | 2016 | 691 | 0.200 |
Why?
| Pesticides | 1 | 2022 | 58 | 0.200 |
Why?
| Severity of Illness Index | 3 | 2021 | 2742 | 0.190 |
Why?
| Volatile Organic Compounds | 1 | 2023 | 57 | 0.190 |
Why?
| Recombinant Proteins | 4 | 2011 | 1304 | 0.190 |
Why?
| Hemolysis | 4 | 2021 | 199 | 0.190 |
Why?
| Arginine | 2 | 2015 | 265 | 0.190 |
Why?
| Metallothionein | 1 | 2021 | 25 | 0.180 |
Why?
| Arterial Occlusive Diseases | 1 | 2021 | 80 | 0.180 |
Why?
| alpha-Thalassemia | 1 | 2020 | 4 | 0.180 |
Why?
| Acute Pain | 1 | 2021 | 45 | 0.180 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2021 | 80 | 0.180 |
Why?
| Extracellular Vesicles | 1 | 2023 | 130 | 0.180 |
Why?
| Desogestrel | 1 | 2021 | 46 | 0.170 |
Why?
| Aged | 11 | 2025 | 22099 | 0.170 |
Why?
| Proteome | 1 | 2025 | 443 | 0.170 |
Why?
| Fertility Preservation | 1 | 2021 | 53 | 0.170 |
Why?
| Purinergic P2Y Receptor Antagonists | 1 | 2021 | 66 | 0.170 |
Why?
| Infertility, Female | 1 | 2021 | 104 | 0.170 |
Why?
| Ecotoxicology | 1 | 2019 | 2 | 0.170 |
Why?
| Vascular Remodeling | 2 | 2019 | 192 | 0.170 |
Why?
| Partial Thromboplastin Time | 2 | 2011 | 52 | 0.160 |
Why?
| Polycyclic Aromatic Hydrocarbons | 2 | 2016 | 27 | 0.160 |
Why?
| Hemorrhage | 2 | 2021 | 678 | 0.160 |
Why?
| Clove Oil | 1 | 2019 | 1 | 0.160 |
Why?
| Eugenol | 1 | 2019 | 3 | 0.160 |
Why?
| Prospective Studies | 9 | 2025 | 7131 | 0.160 |
Why?
| Iron Chelating Agents | 2 | 2011 | 18 | 0.160 |
Why?
| Multiple Organ Failure | 2 | 2005 | 122 | 0.160 |
Why?
| Iron Overload | 2 | 2011 | 12 | 0.160 |
Why?
| Cyprinodontiformes | 1 | 2019 | 6 | 0.160 |
Why?
| Benzoates | 2 | 2011 | 41 | 0.160 |
Why?
| Liver | 3 | 2025 | 1839 | 0.160 |
Why?
| Exercise Tolerance | 2 | 2011 | 273 | 0.160 |
Why?
| Unrelated Donors | 1 | 2019 | 36 | 0.160 |
Why?
| Plastics | 1 | 2019 | 47 | 0.150 |
Why?
| Anesthetics | 1 | 2019 | 66 | 0.150 |
Why?
| Altitude | 3 | 2018 | 461 | 0.150 |
Why?
| Lipids | 2 | 2023 | 625 | 0.150 |
Why?
| Reproducibility of Results | 3 | 2017 | 3083 | 0.150 |
Why?
| Signal Transduction | 2 | 2013 | 4925 | 0.150 |
Why?
| Europe | 2 | 2016 | 364 | 0.140 |
Why?
| Surgical Procedures, Operative | 2 | 2014 | 243 | 0.140 |
Why?
| Triazoles | 2 | 2011 | 152 | 0.140 |
Why?
| Bone Marrow Transplantation | 1 | 2019 | 274 | 0.140 |
Why?
| Aspirin | 1 | 2021 | 380 | 0.140 |
Why?
| Treatment Outcome | 6 | 2025 | 10226 | 0.140 |
Why?
| Lipoproteins | 1 | 2018 | 171 | 0.140 |
Why?
| Prevalence | 4 | 2024 | 2564 | 0.140 |
Why?
| Cohort Studies | 7 | 2018 | 5420 | 0.140 |
Why?
| Physical Exertion | 1 | 2018 | 205 | 0.140 |
Why?
| Climate Change | 1 | 2019 | 165 | 0.140 |
Why?
| Anesthesia | 1 | 2019 | 134 | 0.140 |
Why?
| Factor Analysis, Statistical | 2 | 2016 | 284 | 0.140 |
Why?
| United States | 11 | 2023 | 13900 | 0.140 |
Why?
| Toll-Like Receptor 9 | 1 | 2017 | 31 | 0.140 |
Why?
| Platelet Factor 4 | 2 | 2008 | 34 | 0.130 |
Why?
| Pulmonary Artery | 4 | 2019 | 1096 | 0.130 |
Why?
| Zinc | 1 | 2020 | 294 | 0.130 |
Why?
| Renal Insufficiency, Chronic | 2 | 2019 | 566 | 0.130 |
Why?
| Hypoxia | 3 | 2019 | 1084 | 0.130 |
Why?
| Graft vs Host Disease | 1 | 2019 | 241 | 0.130 |
Why?
| Carps | 1 | 2016 | 2 | 0.130 |
Why?
| Osmeriformes | 1 | 2016 | 1 | 0.130 |
Why?
| Phenylketonurias | 1 | 2016 | 12 | 0.130 |
Why?
| Asia | 1 | 2016 | 58 | 0.130 |
Why?
| Principal Component Analysis | 2 | 2016 | 189 | 0.130 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 759 | 0.130 |
Why?
| Heart Diseases | 1 | 2019 | 350 | 0.130 |
Why?
| Sewage | 1 | 2016 | 29 | 0.130 |
Why?
| Retrospective Studies | 8 | 2021 | 14519 | 0.130 |
Why?
| Erythrocyte Transfusion | 2 | 2015 | 181 | 0.130 |
Why?
| Olfactory Perception | 1 | 2016 | 23 | 0.130 |
Why?
| Infant, Newborn | 5 | 2024 | 5762 | 0.130 |
Why?
| Metals, Heavy | 1 | 2016 | 30 | 0.130 |
Why?
| Rivers | 1 | 2016 | 66 | 0.130 |
Why?
| Macrophages | 2 | 2023 | 1480 | 0.120 |
Why?
| Trace Elements | 1 | 2016 | 49 | 0.120 |
Why?
| Copper | 1 | 2016 | 109 | 0.120 |
Why?
| Thalassemia | 1 | 2015 | 6 | 0.120 |
Why?
| Lung Diseases | 2 | 2019 | 742 | 0.120 |
Why?
| North America | 1 | 2016 | 291 | 0.120 |
Why?
| Fatigue | 1 | 2017 | 318 | 0.120 |
Why?
| Splenic Infarction | 1 | 2014 | 1 | 0.120 |
Why?
| Zebrafish | 1 | 2019 | 458 | 0.120 |
Why?
| Protein S Deficiency | 1 | 1994 | 7 | 0.120 |
Why?
| Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| Blood Component Removal | 1 | 2014 | 26 | 0.110 |
Why?
| Complement Inactivator Proteins | 1 | 1994 | 41 | 0.110 |
Why?
| Quality of Health Care | 2 | 2016 | 608 | 0.110 |
Why?
| Transplantation Conditioning | 1 | 2015 | 166 | 0.110 |
Why?
| Blood Loss, Surgical | 1 | 2014 | 93 | 0.110 |
Why?
| Disease Models, Animal | 5 | 2025 | 4063 | 0.110 |
Why?
| Mice, Inbred C57BL | 5 | 2025 | 5440 | 0.110 |
Why?
| Postoperative Hemorrhage | 1 | 2014 | 87 | 0.110 |
Why?
| Thromboembolism | 1 | 2014 | 112 | 0.110 |
Why?
| Biomarkers | 5 | 2017 | 3973 | 0.110 |
Why?
| Leg Ulcer | 1 | 2013 | 6 | 0.110 |
Why?
| Larva | 2 | 2019 | 214 | 0.110 |
Why?
| Neoplasms | 2 | 2021 | 2470 | 0.100 |
Why?
| Blood Flow Velocity | 2 | 2014 | 404 | 0.100 |
Why?
| Ethinyl Estradiol | 1 | 2012 | 17 | 0.100 |
Why?
| Thrombin | 2 | 2023 | 146 | 0.100 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2013 | 96 | 0.100 |
Why?
| Venous Thrombosis | 2 | 2005 | 176 | 0.100 |
Why?
| Societies, Medical | 1 | 2017 | 751 | 0.100 |
Why?
| Patient Reported Outcome Measures | 1 | 2016 | 372 | 0.100 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 833 | 0.100 |
Why?
| Testosterone | 1 | 2016 | 372 | 0.100 |
Why?
| Sex Factors | 3 | 2019 | 1968 | 0.100 |
Why?
| Preoperative Care | 2 | 2005 | 340 | 0.100 |
Why?
| Chronic Pain | 1 | 2017 | 254 | 0.100 |
Why?
| Ambulatory Care | 1 | 2016 | 504 | 0.100 |
Why?
| Analgesics, Opioid | 3 | 2023 | 913 | 0.100 |
Why?
| Endothelium, Vascular | 1 | 2018 | 901 | 0.100 |
Why?
| Child, Preschool | 10 | 2024 | 10518 | 0.100 |
Why?
| Practice Guidelines as Topic | 3 | 2015 | 1501 | 0.100 |
Why?
| Prostheses and Implants | 2 | 2021 | 133 | 0.090 |
Why?
| Hemoglobin SC Disease | 3 | 1998 | 13 | 0.090 |
Why?
| Mortality | 2 | 2012 | 307 | 0.090 |
Why?
| Hydrogen-Ion Concentration | 1 | 2012 | 544 | 0.090 |
Why?
| Pipecolic Acids | 1 | 2011 | 25 | 0.090 |
Why?
| Creatinine | 2 | 2014 | 491 | 0.090 |
Why?
| Transfusion Reaction | 1 | 2011 | 43 | 0.090 |
Why?
| Mice | 6 | 2025 | 16937 | 0.090 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2013 | 539 | 0.090 |
Why?
| Hemofiltration | 1 | 2010 | 30 | 0.090 |
Why?
| Sulfones | 1 | 2011 | 108 | 0.090 |
Why?
| Disease Progression | 4 | 2023 | 2635 | 0.080 |
Why?
| Awareness | 1 | 2010 | 100 | 0.080 |
Why?
| Disease Management | 2 | 2011 | 589 | 0.080 |
Why?
| Vasodilator Agents | 1 | 2011 | 326 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 2012 | 0.080 |
Why?
| Piperazines | 1 | 2011 | 342 | 0.080 |
Why?
| Career Choice | 1 | 2010 | 207 | 0.080 |
Why?
| Aged, 80 and over | 4 | 2025 | 7084 | 0.070 |
Why?
| Echocardiography | 1 | 2011 | 629 | 0.070 |
Why?
| Pregnancy | 3 | 2005 | 6402 | 0.070 |
Why?
| Drug Utilization Review | 1 | 2008 | 57 | 0.070 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 84 | 0.070 |
Why?
| Anaerobiosis | 1 | 2008 | 57 | 0.070 |
Why?
| Seawater | 1 | 2008 | 26 | 0.070 |
Why?
| Depression | 1 | 2017 | 1307 | 0.070 |
Why?
| Software | 1 | 2013 | 608 | 0.070 |
Why?
| Ventricular Dysfunction, Left | 1 | 2011 | 384 | 0.070 |
Why?
| Kidney Function Tests | 1 | 2008 | 152 | 0.070 |
Why?
| Endothelial Cells | 1 | 2013 | 749 | 0.070 |
Why?
| Cost of Illness | 1 | 2010 | 278 | 0.070 |
Why?
| Oxidation-Reduction | 3 | 2018 | 1033 | 0.070 |
Why?
| Community Participation | 1 | 2009 | 124 | 0.070 |
Why?
| Metabolomics | 1 | 2013 | 652 | 0.070 |
Why?
| Body Size | 1 | 2008 | 102 | 0.070 |
Why?
| Proteomics | 2 | 2025 | 1062 | 0.070 |
Why?
| Lipid Peroxidation | 2 | 2018 | 151 | 0.070 |
Why?
| Registries | 2 | 2023 | 1895 | 0.070 |
Why?
| Histocompatibility Testing | 2 | 2019 | 120 | 0.070 |
Why?
| Deferoxamine | 1 | 2007 | 20 | 0.070 |
Why?
| Double-Blind Method | 3 | 2023 | 1876 | 0.070 |
Why?
| Sulfonamides | 1 | 2011 | 496 | 0.070 |
Why?
| Environmental Exposure | 3 | 2019 | 463 | 0.070 |
Why?
| Chironomidae | 1 | 2006 | 1 | 0.070 |
Why?
| Age Factors | 2 | 2014 | 3144 | 0.070 |
Why?
| Algorithms | 1 | 2014 | 1622 | 0.070 |
Why?
| Acute Kidney Injury | 2 | 2010 | 790 | 0.070 |
Why?
| Rhabdomyolysis | 2 | 2018 | 22 | 0.070 |
Why?
| Social Support | 1 | 2010 | 588 | 0.070 |
Why?
| Urbanization | 2 | 2016 | 27 | 0.070 |
Why?
| Time Factors | 3 | 2019 | 6556 | 0.060 |
Why?
| Fibrinolysis | 2 | 1998 | 137 | 0.060 |
Why?
| Sodium Chloride | 1 | 2006 | 138 | 0.060 |
Why?
| Body Weight | 2 | 2021 | 940 | 0.060 |
Why?
| Coronary Angiography | 1 | 2008 | 306 | 0.060 |
Why?
| Emergency Service, Hospital | 1 | 2016 | 1902 | 0.060 |
Why?
| Dermatan Sulfate | 1 | 2005 | 3 | 0.060 |
Why?
| Species Specificity | 1 | 2006 | 575 | 0.060 |
Why?
| Health Care Surveys | 2 | 2020 | 559 | 0.060 |
Why?
| Factor V | 1 | 2005 | 18 | 0.060 |
Why?
| Captopril | 1 | 2005 | 10 | 0.060 |
Why?
| Heparitin Sulfate | 1 | 2005 | 43 | 0.060 |
Why?
| Chondroitin Sulfates | 1 | 2005 | 35 | 0.060 |
Why?
| Infant Mortality | 1 | 2005 | 104 | 0.060 |
Why?
| Ecosystem | 2 | 2021 | 568 | 0.060 |
Why?
| Survival Analysis | 1 | 2008 | 1274 | 0.060 |
Why?
| Heme Oxygenase-1 | 1 | 2025 | 62 | 0.060 |
Why?
| Angina, Unstable | 1 | 2005 | 76 | 0.060 |
Why?
| Public Health Surveillance | 1 | 2024 | 68 | 0.060 |
Why?
| Needs Assessment | 1 | 2007 | 360 | 0.060 |
Why?
| Polysaccharides | 1 | 2005 | 86 | 0.060 |
Why?
| Risk | 2 | 2005 | 854 | 0.060 |
Why?
| Standard of Care | 1 | 2025 | 72 | 0.060 |
Why?
| Chest Pain | 1 | 2005 | 89 | 0.060 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 78 | 0.060 |
Why?
| Blood Component Transfusion | 1 | 2005 | 82 | 0.060 |
Why?
| Immunoglobulin G | 1 | 2008 | 847 | 0.060 |
Why?
| Practice Patterns, Physicians' | 2 | 2013 | 1266 | 0.050 |
Why?
| Aerosols | 1 | 2025 | 170 | 0.050 |
Why?
| Follow-Up Studies | 3 | 2021 | 4896 | 0.050 |
Why?
| Drug Combinations | 1 | 2005 | 330 | 0.050 |
Why?
| Acute Disease | 2 | 2019 | 980 | 0.050 |
Why?
| Alabama | 1 | 2023 | 38 | 0.050 |
Why?
| Risk Factors | 5 | 2018 | 9763 | 0.050 |
Why?
| Syndrome | 2 | 2014 | 341 | 0.050 |
Why?
| Oxygen | 1 | 2008 | 915 | 0.050 |
Why?
| Simazine | 1 | 2022 | 2 | 0.050 |
Why?
| Glycolysis | 1 | 2025 | 311 | 0.050 |
Why?
| E-Selectin | 1 | 2023 | 54 | 0.050 |
Why?
| Antibodies | 1 | 2005 | 398 | 0.050 |
Why?
| Renal Insufficiency | 1 | 2005 | 149 | 0.050 |
Why?
| Education, Medical, Graduate | 1 | 2007 | 437 | 0.050 |
Why?
| Medical Records | 1 | 2023 | 171 | 0.050 |
Why?
| Healthcare Disparities | 1 | 2009 | 578 | 0.050 |
Why?
| Substance-Related Disorders | 1 | 2011 | 1022 | 0.050 |
Why?
| United Kingdom | 2 | 2014 | 258 | 0.050 |
Why?
| Agriculture | 1 | 2022 | 93 | 0.050 |
Why?
| Coronary Artery Disease | 1 | 2008 | 679 | 0.050 |
Why?
| P-Selectin | 1 | 2021 | 27 | 0.050 |
Why?
| Data Collection | 1 | 2024 | 650 | 0.050 |
Why?
| Incidence | 2 | 2021 | 2644 | 0.050 |
Why?
| Colorado | 3 | 2024 | 4420 | 0.050 |
Why?
| Dietary Exposure | 1 | 2021 | 5 | 0.050 |
Why?
| Oocyte Retrieval | 1 | 2021 | 12 | 0.050 |
Why?
| Vitrification | 1 | 2021 | 7 | 0.050 |
Why?
| Blood Pressure | 3 | 2018 | 1735 | 0.040 |
Why?
| Ovarian Hyperstimulation Syndrome | 1 | 2021 | 8 | 0.040 |
Why?
| Oogenesis | 1 | 2021 | 20 | 0.040 |
Why?
| Ovulation Induction | 1 | 2021 | 55 | 0.040 |
Why?
| Phylogeography | 1 | 2021 | 49 | 0.040 |
Why?
| von Willebrand Factor | 2 | 1998 | 70 | 0.040 |
Why?
| Leukocytes, Mononuclear | 1 | 2023 | 545 | 0.040 |
Why?
| Anti-Mullerian Hormone | 1 | 2021 | 53 | 0.040 |
Why?
| Monocytes | 1 | 2023 | 551 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2016 | 1502 | 0.040 |
Why?
| Cardiac Catheterization | 1 | 2004 | 518 | 0.040 |
Why?
| Luteinizing Hormone | 1 | 2021 | 179 | 0.040 |
Why?
| Cryopreservation | 1 | 2021 | 97 | 0.040 |
Why?
| Australasia | 1 | 2019 | 2 | 0.040 |
Why?
| Metals | 1 | 2021 | 128 | 0.040 |
Why?
| HIV Infections | 1 | 1994 | 2720 | 0.040 |
Why?
| Follicle Stimulating Hormone | 1 | 2021 | 236 | 0.040 |
Why?
| Gonadotropin-Releasing Hormone | 1 | 2021 | 207 | 0.040 |
Why?
| Case-Control Studies | 2 | 2018 | 3381 | 0.040 |
Why?
| Gadolinium | 1 | 2019 | 78 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2005 | 1367 | 0.040 |
Why?
| Rats | 2 | 2019 | 5499 | 0.040 |
Why?
| Tissue Distribution | 1 | 2019 | 315 | 0.040 |
Why?
| Cell Line | 2 | 2015 | 2781 | 0.040 |
Why?
| Proteinuria | 1 | 2018 | 91 | 0.040 |
Why?
| Endothelins | 1 | 2018 | 62 | 0.040 |
Why?
| Allografts | 1 | 2019 | 136 | 0.040 |
Why?
| Guinea Pigs | 1 | 2018 | 157 | 0.040 |
Why?
| Thrombomodulin | 1 | 1998 | 10 | 0.040 |
Why?
| Oxidative Stress | 1 | 2025 | 1269 | 0.040 |
Why?
| Body Height | 1 | 2018 | 193 | 0.040 |
Why?
| Victoria | 1 | 2017 | 16 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2019 | 648 | 0.030 |
Why?
| Pilot Projects | 2 | 2016 | 1587 | 0.030 |
Why?
| Public Health Practice | 1 | 2017 | 64 | 0.030 |
Why?
| Anemia, Hemolytic | 1 | 2017 | 16 | 0.030 |
Why?
| Drug Administration Schedule | 2 | 2011 | 769 | 0.030 |
Why?
| Cytochrome P-450 CYP1A1 | 1 | 2016 | 10 | 0.030 |
Why?
| Fish Proteins | 1 | 2016 | 10 | 0.030 |
Why?
| Acclimatization | 1 | 2018 | 164 | 0.030 |
Why?
| Proteins | 1 | 2023 | 942 | 0.030 |
Why?
| Bile | 1 | 2016 | 35 | 0.030 |
Why?
| Intraoperative Complications | 1 | 1998 | 131 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 1004 | 0.030 |
Why?
| Public-Private Sector Partnerships | 1 | 2017 | 42 | 0.030 |
Why?
| Polychlorinated Biphenyls | 1 | 2016 | 9 | 0.030 |
Why?
| Cross-Sectional Studies | 3 | 2016 | 5066 | 0.030 |
Why?
| Blood Coagulation Factors | 1 | 1996 | 53 | 0.030 |
Why?
| Genetic Markers | 1 | 2017 | 338 | 0.030 |
Why?
| RNA, Messenger | 2 | 2013 | 2708 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2008 | 3408 | 0.030 |
Why?
| Community Health Services | 1 | 2017 | 227 | 0.030 |
Why?
| United States Food and Drug Administration | 1 | 2017 | 204 | 0.030 |
Why?
| Mononuclear Phagocyte System | 1 | 1995 | 11 | 0.030 |
Why?
| Erythrocyte Count | 1 | 1995 | 19 | 0.030 |
Why?
| Erythrocytes, Abnormal | 1 | 1995 | 11 | 0.030 |
Why?
| Silicon Dioxide | 1 | 2016 | 111 | 0.030 |
Why?
| Continuity of Patient Care | 1 | 2017 | 275 | 0.030 |
Why?
| Arginase | 1 | 2015 | 32 | 0.030 |
Why?
| Odorants | 1 | 2016 | 150 | 0.030 |
Why?
| Vitamin B 6 Deficiency | 1 | 1994 | 5 | 0.030 |
Why?
| Excitatory Amino Acids | 1 | 1994 | 7 | 0.030 |
Why?
| Amino Acids, Sulfur | 1 | 1994 | 7 | 0.030 |
Why?
| Cysteic Acid | 1 | 1994 | 1 | 0.030 |
Why?
| beta 2-Glycoprotein I | 1 | 1994 | 4 | 0.030 |
Why?
| Blood Coagulation | 1 | 1996 | 238 | 0.030 |
Why?
| Lupus Coagulation Inhibitor | 1 | 1994 | 5 | 0.030 |
Why?
| Siblings | 1 | 2015 | 215 | 0.030 |
Why?
| Blood Cell Count | 1 | 2014 | 52 | 0.030 |
Why?
| Consensus Development Conferences as Topic | 1 | 2014 | 27 | 0.030 |
Why?
| Antibodies, Anticardiolipin | 1 | 1994 | 8 | 0.030 |
Why?
| Blood Platelets | 1 | 1998 | 380 | 0.030 |
Why?
| Hematocrit | 1 | 2014 | 93 | 0.030 |
Why?
| Health Policy | 1 | 2017 | 353 | 0.030 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2015 | 135 | 0.030 |
Why?
| Automation | 1 | 2014 | 82 | 0.030 |
Why?
| Interview, Psychological | 1 | 2014 | 92 | 0.030 |
Why?
| Echocardiography, Doppler | 1 | 2015 | 108 | 0.030 |
Why?
| Folic Acid Deficiency | 1 | 1994 | 48 | 0.030 |
Why?
| Survival Rate | 1 | 2019 | 1877 | 0.030 |
Why?
| Penicillins | 1 | 2014 | 57 | 0.030 |
Why?
| Hypertrophy, Right Ventricular | 1 | 2015 | 145 | 0.030 |
Why?
| Ferritins | 1 | 2014 | 58 | 0.030 |
Why?
| Vitamin B 12 Deficiency | 1 | 1994 | 78 | 0.030 |
Why?
| Hematologic Tests | 1 | 1994 | 21 | 0.030 |
Why?
| DNA Damage | 1 | 2016 | 384 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 2017 | 443 | 0.030 |
Why?
| Natriuretic Peptide, Brain | 1 | 2014 | 99 | 0.030 |
Why?
| Homocysteine | 1 | 1994 | 152 | 0.030 |
Why?
| Smegmamorpha | 1 | 2013 | 2 | 0.030 |
Why?
| Mood Disorders | 1 | 2014 | 120 | 0.030 |
Why?
| Antibiotic Prophylaxis | 1 | 2014 | 101 | 0.030 |
Why?
| Folic Acid | 1 | 1995 | 184 | 0.030 |
Why?
| Carrier Proteins | 2 | 1995 | 743 | 0.030 |
Why?
| Catalase | 1 | 2013 | 129 | 0.030 |
Why?
| Cell Membrane Permeability | 1 | 2013 | 81 | 0.030 |
Why?
| Vascular Resistance | 1 | 2015 | 371 | 0.030 |
Why?
| Abdominal Pain | 1 | 2014 | 144 | 0.030 |
Why?
| Liver Failure, Acute | 1 | 1994 | 64 | 0.030 |
Why?
| Hemoglobin, Sickle | 1 | 2013 | 18 | 0.030 |
Why?
| Brain Diseases | 1 | 1994 | 137 | 0.030 |
Why?
| Permeability | 1 | 2013 | 157 | 0.030 |
Why?
| Clinical Protocols | 1 | 2014 | 255 | 0.030 |
Why?
| Cysteine | 1 | 1994 | 195 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 30 | 0.030 |
Why?
| Perioperative Care | 1 | 2014 | 152 | 0.030 |
Why?
| Interleukin-6 | 1 | 2017 | 720 | 0.030 |
Why?
| Employment | 1 | 2014 | 167 | 0.030 |
Why?
| Erythrocyte Indices | 1 | 2012 | 27 | 0.030 |
Why?
| Equipment Design | 1 | 2014 | 513 | 0.030 |
Why?
| Receptors, Cell Surface | 1 | 1995 | 380 | 0.030 |
Why?
| Behavior, Animal | 1 | 2016 | 508 | 0.020 |
Why?
| Glycoproteins | 1 | 1994 | 338 | 0.020 |
Why?
| Vascular Diseases | 1 | 2015 | 241 | 0.020 |
Why?
| Choline | 1 | 2013 | 124 | 0.020 |
Why?
| Social Behavior | 1 | 2014 | 289 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2014 | 857 | 0.020 |
Why?
| Inflammation | 1 | 2023 | 2736 | 0.020 |
Why?
| Wounds and Injuries | 1 | 2018 | 711 | 0.020 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2008 | 3628 | 0.020 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 274 | 0.020 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 237 | 0.020 |
Why?
| Macrophages, Alveolar | 1 | 2015 | 389 | 0.020 |
Why?
| Cell-Derived Microparticles | 1 | 2012 | 67 | 0.020 |
Why?
| Physician-Patient Relations | 1 | 2016 | 537 | 0.020 |
Why?
| Public Health | 1 | 2016 | 484 | 0.020 |
Why?
| Toll-Like Receptor 4 | 1 | 2013 | 263 | 0.020 |
Why?
| Health Status | 1 | 2016 | 755 | 0.020 |
Why?
| Physical Therapy Modalities | 1 | 2014 | 292 | 0.020 |
Why?
| Superoxide Dismutase | 1 | 2013 | 342 | 0.020 |
Why?
| Sildenafil Citrate | 1 | 2011 | 59 | 0.020 |
Why?
| Homozygote | 1 | 2011 | 193 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2014 | 1201 | 0.020 |
Why?
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 199 | 0.020 |
Why?
| Hemodynamics | 2 | 2011 | 1089 | 0.020 |
Why?
| Up-Regulation | 1 | 2013 | 840 | 0.020 |
Why?
| Communication | 1 | 2016 | 846 | 0.020 |
Why?
| Respiratory Insufficiency | 1 | 1994 | 313 | 0.020 |
Why?
| Purines | 1 | 2011 | 172 | 0.020 |
Why?
| Mice, Knockout | 1 | 2017 | 2871 | 0.020 |
Why?
| Metabolome | 1 | 2013 | 338 | 0.020 |
Why?
| Pediatrics | 1 | 2017 | 1052 | 0.020 |
Why?
| NF-kappa B | 1 | 2013 | 653 | 0.020 |
Why?
| Walking | 1 | 2014 | 501 | 0.020 |
Why?
| Erythrocytes | 1 | 1995 | 672 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2015 | 2406 | 0.020 |
Why?
| Cell Proliferation | 1 | 2017 | 2391 | 0.020 |
Why?
| Gastrointestinal Diseases | 1 | 2011 | 198 | 0.020 |
Why?
| Pneumonia | 1 | 2015 | 616 | 0.020 |
Why?
| Databases, Factual | 1 | 2014 | 1269 | 0.020 |
Why?
| Sepsis | 1 | 1995 | 574 | 0.020 |
Why?
| Exercise Test | 1 | 2011 | 613 | 0.020 |
Why?
| Gene Expression | 1 | 2013 | 1472 | 0.020 |
Why?
| Genotype | 1 | 2013 | 1839 | 0.020 |
Why?
| Comorbidity | 1 | 2012 | 1547 | 0.020 |
Why?
| Infant | 3 | 2014 | 9025 | 0.020 |
Why?
| Chelation Therapy | 1 | 2007 | 11 | 0.020 |
Why?
| Postoperative Complications | 1 | 2018 | 2483 | 0.020 |
Why?
| Health Personnel | 1 | 2013 | 652 | 0.020 |
Why?
| Calcinosis | 1 | 2008 | 230 | 0.020 |
Why?
| Cardiovascular Diseases | 1 | 2018 | 2004 | 0.020 |
Why?
| Diabetic Angiopathies | 1 | 2008 | 261 | 0.020 |
Why?
| Alanine Transaminase | 1 | 2007 | 153 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2016 | 1614 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2011 | 1952 | 0.020 |
Why?
| Health Services | 1 | 2007 | 99 | 0.020 |
Why?
| Mental Disorders | 1 | 1994 | 1030 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 1721 | 0.020 |
Why?
| Critical Illness | 1 | 2010 | 758 | 0.010 |
Why?
| Program Development | 1 | 2007 | 357 | 0.010 |
Why?
| Administration, Oral | 1 | 2007 | 786 | 0.010 |
Why?
| Gas Chromatography-Mass Spectrometry | 2 | 1995 | 131 | 0.010 |
Why?
| Isotope Labeling | 2 | 1995 | 74 | 0.010 |
Why?
| Academic Medical Centers | 1 | 2007 | 481 | 0.010 |
Why?
| Logistic Models | 1 | 2008 | 1988 | 0.010 |
Why?
| Respiratory Tract Infections | 1 | 2007 | 376 | 0.010 |
Why?
| Referral and Consultation | 1 | 2007 | 733 | 0.010 |
Why?
| Attitude of Health Personnel | 1 | 2008 | 1095 | 0.010 |
Why?
| Insulin Resistance | 1 | 2008 | 1165 | 0.010 |
Why?
| Delivery of Health Care | 1 | 2007 | 893 | 0.010 |
Why?
| Physicians | 1 | 2008 | 864 | 0.010 |
Why?
| Liver Function Tests | 1 | 1996 | 112 | 0.010 |
Why?
| Respiration | 1 | 1996 | 191 | 0.010 |
Why?
| Folate Receptors, GPI-Anchored | 1 | 1995 | 5 | 0.010 |
Why?
| 4-Aminobenzoic Acid | 1 | 1995 | 7 | 0.010 |
Why?
| Vacuoles | 1 | 1995 | 36 | 0.010 |
Why?
| Lactobacillus | 1 | 1995 | 26 | 0.010 |
Why?
| Radionuclide Imaging | 1 | 1995 | 123 | 0.010 |
Why?
| Reference Standards | 1 | 1995 | 177 | 0.010 |
Why?
| Carbon Isotopes | 1 | 1995 | 126 | 0.010 |
Why?
| Aspartic Acid | 1 | 1994 | 81 | 0.010 |
Why?
| Neurotransmitter Agents | 1 | 1994 | 81 | 0.010 |
Why?
| Deuterium | 1 | 1994 | 87 | 0.010 |
Why?
| Disease Susceptibility | 1 | 1995 | 333 | 0.010 |
Why?
| Reference Values | 1 | 1994 | 793 | 0.010 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 1994 | 212 | 0.010 |
Why?
| Cattle | 1 | 1995 | 976 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 1995 | 1838 | 0.010 |
Why?
| Brain | 1 | 1994 | 2679 | 0.000 |
Why?
|
|
Hassell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|